example 36 [WO2016177845]   Click here for help

GtoPdb Ligand ID: 9555

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Example 36 is one of a number of leukotriene C4 synthase (LTC4S) inhibitors claimed in AstraZeneca patent WO2016177845 [2], particularly for the treatment of respiratory diseases and inflammation. In support of this enzyme as a drug target, a paper by Kleinschmidt et al. (2015) [1] demonstrates that LTC4S inhibitors block leukotriene C4 and cys-LT synthesis in vitro and in vivo, but note that their inhibitors are of quite different structure compared to example 36.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 79.73
Molecular weight 442.19
XLogP 4.01
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(cnc1C(=O)C1CC1C(=O)O)N(c1ccc2c3c1cccc3CC2)CC1CC1
Isomeric SMILES COc1cc(cnc1C(=O)C1CC1C(=O)O)N(c1ccc2c3c1cccc3CC2)CC1CC1
InChI InChI=1S/C27H26N2O4/c1-33-23-11-18(13-28-25(23)26(30)20-12-21(20)27(31)32)29(14-15-5-6-15)22-10-9-17-8-7-16-3-2-4-19(22)24(16)17/h2-4,9-11,13,15,20-21H,5-8,12,14H2,1H3,(H,31,32)
InChI Key FQHWQFIPEVBFKT-UHFFFAOYSA-N
Immunopharmacology Comments
For asthma, reduction of cys-LTs production (which are potent bronchoconstrictors and proinflammatory mediators) by blocking LTC4S would be an approach that circumvents multiple receptors to reduce airway inflammation [1].
Immunopharmacology Disease
Disease X-Refs Comment References
Asthma Disease Ontology: DOID:2841
OMIM: 600807
A novel LTC4S inhibitor with potential anti-inflammatory effects in respiratory conditions such as asthma. 1